If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT02805556","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"http://","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":"true"},"PatientLevelData":"false","SharingIpd":"None","acronym":"","allocation":"N/A","arm_groups":[{"arm_group_label":"Oral dose of BMS-663068 + intravenous dose of [13C]BMS 626529","arm_group_description":"Single oral dose of BMS-663068 followed by Single intravenous dose of [13C]BMS 626529","arm_type":"Experimental"}],"assignment":"Single Group Assignment","brief_summary":"A phase I absolute bioavailability study of BMS-626529 following oral and intravenous dosing","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Absolute bioavailability of BMS-626529 after oral and intravenous dosing","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:36:42","criteria":"Inclusion Criteria: - Generally healthy - BMI 18.0-32.0 kg/m2 - Men sexually active with women of childbearing potential must follow instructions for contraception for the duration of treatment plus 90 days - Men must refrain from sperm donation for the length of the study and for 90 days - Sign informed consent Exclusion Criteria: - Significant medical illness - Tobacco use in the last 12 months - Major surgery within 4 weeks of study administration - Donation of blood within 4 weeks of study administration - Current or recent (within 3 months of study administration) of gastrointestinal disease","detailed_description":"","display_gender":"Male","display_gender_internal":"GENDER_MALE","display_phase":"Phase 1","display_phase_internal":"PHASE_1","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"36","exclusion":"","gender":"Male","gender_based":"","gender_description":"","healthy_volunteers":"Yes","id":"87f66cbd-b474-5ea0-bbde-f1f472ad1134","internal":{"content":null,"contentDigest":"ca9af3aed8f2de7030025470a19fe786","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Generally healthy - BMI 18.0-32.0 kg/m2 - Men sexually active with women of childbearing potential must follow instructions for contraception for the duration of treatment plus 90 days - Men must refrain from sperm donation for the length of the study and for 90 days - Sign informed consent Exclusion Criteria: - Significant medical illness - Tobacco use in the last 12 months - Major surgery within 4 weeks of study administration - Donation of blood within 4 weeks of study administration - Current or recent (within 3 months of study administration) of gastrointestinal disease","interventions":[{"arm_group_label":"Oral dose of BMS-663068 + intravenous dose of [13C]BMS 626529","intervention_description":"Single oral dose of BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"Oral dose of BMS-663068 + intravenous dose of [13C]BMS 626529","intervention_description":"Single intravenous dose of [13C]BMS 626529","intervention_name":"BMS-626529","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":[],"last_follow_up_date":"05/05/2016 00:00:00","links":[],"locations":[{"City":"Lisburn","Latitude":"54.5020638","CountryDisplay":"United Kingdom","Longitude":"-6.1010569","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"BT 28 2 RF","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"","maximum_age_raw":"50 years","maximum_age":"50","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:43:52","number_of_arms":"1","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"Study of the Absolute Bioavailability of BMS-626529 in Healthy Subjects Following Oral Dosing of BMS-663068 and Intravenous Dosing of BMS-626529","org_study_id":"206218","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":null,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"1","primary_compl_date":"05/05/2016 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"The absolute bioavailability of BMS-626529 after single oral (BMS-663068) and single intravenous dosing ([13C]-BMS-626529) by assessing the primary endpoints AUC(inf)","outcome_time_frame":"up to 11 days","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[{"id":"AI438-075","id_type":"Other Identifier","id_domain":"Bristol-Myers Squibb"}],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Safety and tolerability of single oral dose of BMS-663068 as determined by medical review of adverse event reports, vital sign measurements, electrocardiograms (ECGs), and results of physical examination and laboratory tests","outcome_time_frame":"up to 31 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Safety and tolerability of single intravenous dose of [13C]-BMS-626529 as determined by medical review of adverse event reports, vital sign measurements, electrocardiograms (ECGs), and results of physical examination and laboratory tests","outcome_time_frame":"up to 31 days","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GlaxoSmithKline"]},"start_date":"03/15/2016 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":false}},"pageContext":{"studyId":"206218"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}